PhotoPharmics finishes pivotal Parkinson’s light therapy trial

By AI, Created 4:22 PM UTC, May 18, 2026, /AGP/ – PhotoPharmics says it has completed its 351-patient Phase 3 Light for PD study of the investigational Celeste device and will present topline results May 26 at the World Parkinson Congress in Phoenix. The readout could shape the company’s next regulatory step: a planned De Novo submission to the FDA.

Why it matters: - PhotoPharmics’ trial completion is a major milestone for Celeste, its investigational photo-neuromodulation device for Parkinson’s disease. - The study could add to treatment options for motor and non-motor symptoms that existing therapies do not fully address. - The company plans to use the data to support regulatory next steps, including a De Novo submission to the FDA.

What happened: - PhotoPharmics announced Last Patient Last Visit in its pivotal Phase 3 Light for PD clinical trial on May 15, 2026. - The trial enrolled 351 people with Parkinson’s disease across the United States. - The University of Rochester Medicine Clinical Trials Coordination Center handled all participant visits and trial coordination. - PhotoPharmics will present topline results on May 26 at 7:45 a.m. in Room 224 at the World Parkinson Congress in Phoenix, which runs May 25-27. - The company will also exhibit at Booth #520 during the congress.

The details: - Light for PD was fully remote and required no clinic visits. - The study used a randomized, double-blind, sham-controlled design. - Participants used Celeste at home, with digital tools supporting daily use and structured outcome assessments. - The trial evaluated outcomes across both motor and non-motor measures. - With participant activity complete, PhotoPharmics will move to database lock and final data analysis. - Celeste is designed to deliver precisely tuned light through the eyes to engage melanopsin-containing intrinsically photosensitive retinal ganglion cells, or ipRGCs, and associated neural pathways. - PhotoPharmics says those pathways are believed to affect circadian regulation, sleep and related dysfunction. - Celeste has received Breakthrough Device designation from the U.S. Food and Drug Administration. - Celeste remains investigational, is not authorized for marketing in any jurisdiction, and is limited by U.S. law to investigational use. - The device is not CE marked and is not available for use in the EU. - PhotoPharmics is a privately held medical device company based in Salt Lake City. - The company says its founders have more than 30 years of experience in light-based neuroscience.

Between the lines: - The fully remote design is notable because it tested whether a Parkinson’s trial can be run at national scale without site visits or travel. - The study also reflects growing interest in the link between circadian biology and Parkinson’s disease, a connection the lead investigator described as building in the scientific literature for years. - PhotoPharmics is positioning Celeste as a non-invasive approach, but the real test will be whether the topline data show meaningful clinical benefit.

What’s next: - PhotoPharmics will analyze the locked dataset after the trial readout. - The company plans to advance regulatory activity after the data presentation. - Investors, clinicians and patients will be watching the Phoenix presentation for evidence that the device can help both motor and non-motor Parkinson’s symptoms.

The bottom line: - PhotoPharmics has cleared a key execution hurdle, and the next inflection point is the May 26 topline data readout.